This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The investigators will test the prediction that escitalopram has a positive effect on glycemic control in type 2 diabetics. The investigators will monitor HgbA1C levels over a 24-week placebo controlled trial of escitalopram. Our hypothesis is that escitalopram will not only avoid previously documented adverse effects of other agents such a tricyclic antidepressants (TCA) on glycemic control, but indeed will improve glycemic control compared to placebo. The investigators will confirm that escitalopram is a clinically effective, well-tolerated antidepressant in patients with type 2 diabetes. The investigators will administer escitalopram in a clinically appropriate fashion including dose titration if indicated. The hypothesis is that subject clinical response will parallel existing clinical data on medication effectiveness. The investigators will monitor affective improvement as evidenced by previously validated instruments for depression and dysteymia. The hypothesis is that improvements in depression scores will parallel existing instrument outcomes from previous clinical trials.
Showing the most recent 10 out of 211 publications
